CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.79B, above the global median of $1.18B
- PositionGross margin is 79.9%, higher than 95% of its Medical Devices peers (median 58.7%)
- Interpretations6 currently firing — 6
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
3.46%Above 5Y avg (2.56%)
Annual Rate
CNY 0.52Paid annual
Payout Ratio
77.6%Moderate
Payback Period
29.4 yr
Last Ex-Dividend
Jun 1, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
11.99BCNY1.79B · vs all stocks (USD)
Trailing P/E
22.40xvs Medical Devices peers
Revenue (TTM)
1.91BCNY284.99M · vs all stocks (USD)
Profit Margin
27.49%vs Medical Devices peers
Beta
0.3090xvs all stocks
52-Week Change
-33.02%vs all stocks
Market Capitalization
11.99BCNY1.79B · vs all stocks (USD)
Enterprise Value
10.48BCNY1.56B · vs all stocks (USD)
Trailing P/E
22.40xvs Medical Devices peers
Forward P/E
8.93xvs Medical Devices peers
Price to Sales (TTM)
6.28xvs Medical Devices peers
Price to Book (MRQ)
3.36xvs Medical Devices peers
Enterprise to Revenue
5.49xvs Medical Devices peers
Enterprise to EBITDA
13.21xvs Medical Devices peers
Gross Margin
79.89%vs Medical Devices peers
Profit Margin
27.49%vs Medical Devices peers
Operating Margin
36.80%vs Medical Devices peers
Return on Assets (TTM)
8.09%vs Medical Devices peers
Return on Equity (TTM)
15.98%vs Medical Devices peers
Revenue (TTM)
1.91BCNY284.99M · vs all stocks (USD)
Revenue per Share (TTM)
2.45CNYUpdated Sep 20, 2026Quarterly Revenue Growth
-19.60%vs Medical Devices peers
Gross Profit (TTM)
1.47BCNY218.80M · vs all stocks (USD)
EBITDA (TTM)
924.19MCNY137.91M · vs all stocks (USD)
Net Income (TTM)
525.07MCNY78.35M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-19.60%vs Medical Devices peers
Operating Cash Flow (TTM)
594.15MCNY88.66M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
149.73MCNY22.34M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.5200CNYUpdated Sep 20, 2026Trailing Annual Dividend Yield
3.46%vs all stocks
5-Year Average Dividend Yield
2.56%vs all stocks
Payout Ratio
77.61%vs Medical Devices peers
Minority Interest (Equity)
-391.82KCNYFY2025 · Dec 31, 2025Revenue
2.01BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
428.50MCNYFY2025 · Dec 31, 2025Gross Profit
1.58BCNYFY2025 · Dec 31, 2025Operating Income
739.52MCNY110.35M · vs all stocks (USD)
Pre-tax Income
660.13MCNYFY2025 · Dec 31, 2025Income Tax Expense
128.46MCNYFY2025 · Dec 31, 2025Net Income
531.67MCNYFY2025 · Dec 31, 2025EBIT
713.64MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
896.71MCNYFY2025 · Dec 31, 2025Research & Development
198.45MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
276.92MCNYFY2025 · Dec 31, 2025Other Operating Expenses
36.79MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
14.47MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
53.51MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.6900CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.6900CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
772.20MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
772.20MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
531.67MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
1.15MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
641.15MCNYFY2025 · Dec 31, 2025Free Cash Flow
471.42MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
2.47BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
531.67MCNYFY2025 · Dec 31, 2025Other Non-cash Items
67.26MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
10.65MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
31.57MCNYFY2025 · Dec 31, 2025Capital Expenditures
-169.73MCNYFY2025 · Dec 31, 2025Purchase of Investments
-3.77BCNYFY2025 · Dec 31, 2025Sale of Investments
4.59BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
643.15MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
100.27MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-263.43MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-643.57MCNYFY2025 · Dec 31, 2025Other Financing Charges
243.39MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-563.33MCNYFY2025 · Dec 31, 2025Shares Outstanding
798.61MSharesUpdated Sep 20, 2026Float Shares
374.61MSharesUpdated Sep 20, 2026% Held by Insiders
50.39%vs all stocks
% Held by Institutions
6.08%vs all stocks
Total Cash (MRQ)
2.38BCNY355.60M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.08CNYUpdated Sep 20, 2026Total Debt (MRQ)
1.24BCNY184.60M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3576xvs Medical Devices peers
Current Ratio (MRQ)
2.11xvs Medical Devices peers
Book Value per Share (MRQ)
4.47CNYUpdated Sep 20, 2026Total Assets
5.41BCNY807.12M · vs all stocks (USD)
Total Current Assets
2.92BCNYFY2025 · Dec 31, 2025Total Liabilities
1.94BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.49BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.44BCNYFY2025 · Dec 31, 2025Total Current Liabilities
502.10MCNYFY2025 · Dec 31, 2025Cash
2.24BCNYFY2025 · Dec 31, 2025Cash Equivalents
275.84MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.52BCNYFY2025 · Dec 31, 2025Other Short-term Investments
61.82KCNYFY2025 · Dec 31, 2025Accounts Receivable
29.26MCNYFY2025 · Dec 31, 2025Inventory
291.75MCNYFY2025 · Dec 31, 2025Accounts Payable
112.27MCNYFY2025 · Dec 31, 2025Short-term Debt
47.99MCNYFY2025 · Dec 31, 2025Other Current Liabilities
6.51MCNYFY2025 · Dec 31, 2025Long-term Debt
1.19BCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
3.02MCNYFY2025 · Dec 31, 2025Common Stock (Book)
798.61MCNYFY2025 · Dec 31, 2025Retained Earnings
2.43BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.47BCNY517.99M · vs all stocks (USD)
Treasury Stock
500.06MCNYFY2025 · Dec 31, 202552-Week Low
14.73CNYUpdated Sep 20, 202652-Week High
22.93CNYUpdated Sep 20, 202652-Week Change
-33.02%vs all stocks
Beta
0.3090xvs all stocks
50-Day MA
16.44CNYUpdated Sep 20, 2026200-Day MA
18.14CNYUpdated Sep 20, 2026Avg 10-Day Volume
3.40MSharesUpdated Sep 20, 2026Avg 30-Day Volume
6.64MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
0.6700CNYUpdated Sep 20, 20266 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 79.9%, higher than 95% of its Medical Devices peers (median 58.7%)Significant
Gross margin: 0.80Industry median: 0.59Industry P95: 0.79Peers compared: 60.00
Financial Health
Altman Z-Score 5.68: safe zoneNotable
Altman Z-Score: 5.68
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.79B, above the global median of $1.18BNotable
Market cap (USD): 1,788,709,865.712Global Median: 1,180,223,658.953
Levered free cash flow is $22.34M, above the global median of $18.73MNotable
Levered free cash flow (USD): 22,342,335.759Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Eris Lifesciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Xeris Biopharma Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zenas BioPharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Vir Biotechnology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Rhodiola Pharmaceutical Holding Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
PolyPeptide Group AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cohance Lifesciences Limited
Tier 1ProductionApproval-Gated PipelineRule
Alivus Life Sciences Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
4DMedical Limited
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Wedge Industrial Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Shenzhen New Industries Biomedical Engineering Co., Ltd.
5 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
PharmaEngine, Inc.
5 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
Hebei Broadcasting & TV Information Network Co. Ltd.
6 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash-Flow Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels